Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Feb;37(2):183–186. doi: 10.1128/aac.37.2.183

In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis.

D R Ashtekar 1, R Costa-Perira 1, K Nagrajan 1, N Vishvanathan 1, A D Bhatt 1, W Rittel 1
PMCID: PMC187635  PMID: 8452346

Abstract

CGI 17341 (2-ethyl-5-nitro-2,3-dihydro[2-1b]imidazo-oxazole) is a novel orally active representative of the 5-nitroimidazole series of antimicrobial agents. At concentrations ranging from 0.1 to 0.3 micrograms/ml, CGI 17341 inhibited the drug-susceptible and multi-drug-resistant strains of Mycobacterium tuberculosis. CGI 17341 had no cross-resistance with isoniazid, rifampin, streptomycin, or ethambutol. While the in vitro activity of CGI 17341 against M. tuberculosis was comparable to those of isoniazid and rifampin, it was superior to those of streptomycin, ciprofloxacin or norfloxacin, and oxazolidinone DuP 721. The MIC of CGI 17341 was not affected when the pH of the medium was decreased from 6.8 to 5.6, while four- to sixfold increases in the MICs of ciprofloxacin and isoniazid were observed. In mice infected with M. tuberculosis, the 50% effective dose for CGI 17341 was 7.7 mg/kg of body weight (95% confidence limits, 3.5 and 10.27) when administered on days 11 and 12 postinfection. CGI 17341 gave a dose-dependent (r = 0.995) and significant increase in the survival time. Our data indicate that the 5-nitroimidazole CGI 17341 is a promising and novel antituberculosis compound with potent in vitro and in vivo activities. Further investigations on this compound are warranted.

Full text

PDF
183

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashtekar D. R., Costa-Periera R., Shrinivasan T., Iyyer R., Vishvanathan N., Rittel W. Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn Microbiol Infect Dis. 1991 Nov-Dec;14(6):465–471. doi: 10.1016/0732-8893(91)90002-w. [DOI] [PubMed] [Google Scholar]
  2. Aziz A., Siddiqi S. H., Aziz K., Ishaq M. Drug resistance of Mycobacterium tuberculosis isolated from treated patients in Pakistan. Tubercle. 1989 Mar;70(1):45–51. doi: 10.1016/0041-3879(89)90064-0. [DOI] [PubMed] [Google Scholar]
  3. Bartlett J. G. Anti-anaerobic antibacterial agents. Lancet. 1982 Aug 28;2(8296):478–481. doi: 10.1016/s0140-6736(82)90503-7. [DOI] [PubMed] [Google Scholar]
  4. Carmine A. A., Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Tinidazole in anaerobic infections: a review of its antibacterial activity, pharmacological properties and therapeutic efficacy. Drugs. 1982 Aug;24(2):85–117. doi: 10.2165/00003495-198224020-00001. [DOI] [PubMed] [Google Scholar]
  5. Cuchural G. J., Jr, Tally F. P., Jacobus N. V., Aldridge K., Cleary T., Finegold S. M., Hill G., Iannini P., O'Keefe J. P., Pierson C. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother. 1988 May;32(5):717–722. doi: 10.1128/aac.32.5.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Goldman P. The development of 5-nitroimidazoles for the treatment and prophylaxis of anaerobic bacterial infections. J Antimicrob Chemother. 1982 Aug;10 (Suppl A):23–33. doi: 10.1093/jac/10.suppl_a.23. [DOI] [PubMed] [Google Scholar]
  7. Gudmundsson A., Erlendsdottir H., Gottfredsson M., Gudmundsson S. Impact of pH and cationic supplementation on in vitro postantibiotic effect. Antimicrob Agents Chemother. 1991 Dec;35(12):2617–2624. doi: 10.1128/aac.35.12.2617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ji B., Truffot-Pernot C., Grosset J. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Tubercle. 1991 Sep;72(3):181–186. doi: 10.1016/0041-3879(91)90004-c. [DOI] [PubMed] [Google Scholar]
  9. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle. 1991 Mar;72(1):1–6. doi: 10.1016/0041-3879(91)90017-m. [DOI] [PubMed] [Google Scholar]
  10. Kradolfer F. Rifampicin, isoniazid, ethambutol, ethionamide, and streptomycin in murine tuberculosis: comparative chemotherapeutic studies. Antibiot Chemother. 1970;16:352–360. doi: 10.1159/000386838. [DOI] [PubMed] [Google Scholar]
  11. Ormerod L. P., Harrison J. M., Wright P. A. Drug resistance trends in Mycobacterium tuberculosis: Blackburn 1985-89. Tubercle. 1990 Dec;71(4):283–285. doi: 10.1016/0041-3879(90)90042-7. [DOI] [PubMed] [Google Scholar]
  12. Smith S. M., Eng R. H., Cherubin C. E. Conditions affecting the results of susceptibility testing for the quinolone compounds. Chemotherapy. 1988;34(4):308–314. doi: 10.1159/000238584. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES